申请人:Grobelny Damian W.
公开号:US20120034270A1
公开(公告)日:2012-02-09
The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with in-appropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.
本发明涉及一种具有S1P受体调节活性的新化合物,优选具有凋亡活性和/或抗癌细胞和其他细胞类型增殖活性。此外,本发明涉及一种药物,包括本发明中至少一种化合物,用于治疗由于或与不适当的S1P受体调节活性或表达相关的疾病和/或状况,例如癌症。本发明的另一方面涉及使用包括本发明中至少一种化合物的药物制造药物,用于治疗由于或与不适当的S1P受体调节活性或表达相关的疾病和/或状况,例如癌症。